DM-199

DiaMedica's DM199, a recombinant human tissue kallikrein-1, demonstrates promising potential in acute ischemic stroke treatment by enhancing collateral circulation and stimulating angiogenesis.

IDEAYA Biosciences advances multiple oncology programs, with over 230 patients enrolled in potential registration-enabling trial for darovasertib in metastatic uveal melanoma, targeting key readouts by end of 2025.

Stellenbosch University initiates a clinical trial for DM199, a novel drug targeting the root cause of preeclampsia, a severe pregnancy complication.

DiaMedica Therapeutics modified its ReMEDy2 trial for acute ischemic stroke, including thrombolytic non-responders and increasing interim analysis sample size to 200 subjects.

DiaMedica Therapeutics gains approval from SAHPRA to begin a Phase II clinical trial of DM199 for preeclampsia treatment.